On Buying Spree, Colby Pharma Builds A Clinical Stage Portfolio
This article was originally published in The Pink Sheet Daily
Executive Summary
The privately-held Colby Pharmaceutical Company is building a portfolio of drugs through several in-licensing deals, the latest of which is with Mannkind for rights to disease-specific antigen compounds and intra-lymph node delivery technologies from a novel cancer immunotherapy program.
You may also be interested in...
Deals Of The Week: Forest/Adamas, Colby/MannKind, Pernix/Cypress/Hawthorn
Building on the 10-pharma clinical development problem-solving initiative launched in September, J&J, Merck and Lilly are spearheading a databank that will share information on clinical trial sites and investigators, with a primary goal of avoiding redundancy in paperwork and training.
MannKind Shares Game Plan For Tackling Afrezza's Complete Response
Execs fend off criticism for taking so long to release complete response letter news, and share plan to adapt ongoing trials to meet new FDA demands. But some analysts are not convinced.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.